AI Article Synopsis
- The study investigates the roles of hepatoma-derived growth factor (HDGF) and β-catenin in synovial sarcoma, highlighting their importance as independent prognostic factors for patient survival.
- HDGF knockdown led to reduced cell growth and increased cell death in synovial sarcoma cells, while recombinant HDGF boosted cell proliferation.
- There is a reciprocal relationship between HDGF and β-catenin, with their interaction playing a key role in the development of synovial sarcoma tumorigenesis.
Article Abstract
To clarify the clinicopathological and biological role of hepatoma-derived growth factor (HDGF) and β-catenin in synovial sarcoma. Our results showed that histological type and HDGF/β-catenin expression were the two important independent prognostic factors for overall survival in synovial sarcoma patients. HDGF knockdown dramatically inhibited cellular proliferation, colony formation, and migration but induced G1 phase arrest and apoptosis in SW982 cells. Recombinant HDGF enhanced synovial sarcoma cell growth and partially retrieved the cell growth suppression in SW982 cells upon HDGF knockdown. HDGF knockdown dramatically suppressed β-catenin and its downstream gene expression in SW982 cells. Intriguingly, β-catenin knockdown dramatically suppressed HDGF expression in SW982 cells. A direct interaction of HDGF and β-catenin was found in SW982 cells. Three HDGF-binding elements in β-catenin promoter were found and specific for transcriptional activation of β-catenin in SW982 cells. In conclusion, our findings first indicate that the interaction of HDGF and β-catenin may play a crucial role in tumorigenesis of synovial sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s13277-016-4905-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrative metabolomic-proteomic analysis uncovers a new therapeutic approach in targeting rheumatoid arthritis.
Arthritis Res Ther
December 2024
Integrative and Functional Biology Department, Council of Scientific & Industrial Research (CSIR)-Institute of Genomics and Integrative Biology, Mall Road, Delhi University Campus, Delhi, 110007, India.
Objective: Rheumatoid arthritis (RA) is a chronic inflammatory condition that, despite available approaches to manage the disease, lacks an efficient treatment and timely diagnosis. Using the most advanced omics technique, metabolomics and proteomics approach, we explored varied metabolites and proteins to identify unique metabolite-protein signatures involved in the disease pathogenesis of RA.
Methods: Untargeted metabolomics (n = 20) and proteomics (n = 60) of RA patients' plasma were carried out by HPLC/LC-MS/MS and SWATH, respectively and analyzed by Metaboanalyst.
Alpha-Taxilin: A Potential Diagnosis and Therapeutics Target in Rheumatoid Arthritis Which Interacts with Key Glycolytic Enzymes Associated with Metabolic Shifts in Fibroblast-Like Synoviocytes.
J Inflamm Res
November 2024
Council of Scientific & Industrial Research (CSIR), Institute of Genomics and Integrative Biology, Delhi University Campus, Delhi, 110007, India.
Article Synopsis
- Rheumatoid Arthritis (RA) is a chronic autoimmune disease, and previous research highlighted α-Taxilin as a key protein elevated in RA, necessitating further exploration of its role in the disease.
- In a study involving 106 RA patients, α-Taxilin levels were significantly higher compared to those with osteoarthritis, systemic lupus erythematosus, and healthy individuals, and it correlated with RA severity markers.
- The study identified 17 proteins interacting with α-Taxilin, suggesting its involvement in key metabolic pathways, and experiments showed that reducing α-Taxilin levels lowered inflammation and improved symptoms in both cell cultures and a rat model of arthritis.
Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis.
RMD Open
November 2024
Department of Immunology and Infection, Biomedical Research Institute, UHasselt, Hasselt, Belgium
Objective: To discover antibody biomarkers that can predict a lack of response to first-line therapy in rheumatoid arthritis (RA) patients.
Methods: Two RA cDNA phage display libraries were screened for novel antibodies in baseline RA sera from the Care in early RA (CareRA) trial, differentiating between patients who did or did not reach remission after first-line therapy (n=20 each). Antibody reactivity to identified University Hasselt (UH)-RA antigens was validated in baseline samples from 136 additional CareRA participants.
Identification of the active constituents and molecular mechanism of Eulophia nuda extract in the treatment of osteoarthritis by network pharmacology, molecular modelling and experimental assays.
Naunyn Schmiedebergs Arch Pharmacol
September 2024
Centre for Biotechnology, Siksha 'O' Anusandhan (Deemed to be University), Kalinganagar, Ghatikia, Bhubaneswar, Odisha, 751003, India.
Osteoarthritis is a degenerative joint disease that worsens over time, often resulting in chronic pain. Eulophia nuda (Orchidaceae), a medicinal herb widely used by folklore and indigenous healers for treating arthritis but the active ingredients and the molecular mechanisms of action are yet to be explored. The present study systematically investigates the underlying anti-osteoarthritic mechanism of ENE through network pharmacology, molecular dynamics simulation and experimental assays.
View Article and Find Full Text PDFMitoregulin modulates inflammation in osteoarthritis: Insights from synovial transcriptomics and cellular studies.
Biochem Biophys Res Commun
November 2024
Department of Biochemistry, Department of Convergence Medical Science, and Institute of Medical Science, Gyeongsang National University School of Medicine, Jinju, Republic of Korea. Electronic address:
Osteoarthritis is a prevalent musculoskeletal disease that involves cartilage degradation, subchondral bone remodeling, and synovial inflammation and ultimately causes physical disability. Common risk factors for osteoarthritis include age, sex, obesity, and genetic predispositions. Treatment includes nonpharmaceutical and pharmacological approaches; however, disease-modifying osteoarthritis drugs remain undeveloped.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!